BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced its financial results for the quarter ended June 30, 2018.
Second Quarter and Recent Developments
- Received FDA approval of Imvexxy™ (estradiol vaginal inserts) on May 29, 2018 for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy (VVA), due to menopause.
- Completed the first drawdown of $75 million on June 7, 2018 under its previously announced $200 million term loan facility with MidCap Financial, managed by Apollo Capital Management, L.P, to support the commercial launch of its recently approved product.
- Initiated Imvexxy’s limited launch (early experience program) on July 9, 2018 with the 10 mcg dose, which will be followed by the national launch of the 10 mcg dose that is expected to commence on August 6, 2018. In the first three weeks of limited launch (July 9-27, 2018), approximately 1,363 healthcare providers have initiated at least one patient on treatment and sent in the follow-on prescription for continuation of treatment on the maintenance pack. The 4 mcg dose of Imvexxy is expected to be available in early September 2018.
- Net revenue for the company’s prescription prenatal vitamin business was approximately $3.8 million for the second quarter of 2018, compared with approximately $4.3 million for the second quarter of 2017.
- Net loss was approximately $33.2 million for the second quarter of 2018, compared with approximately $19.7 million for the second quarter of 2017.
- Ended the quarter with approximately $154.4 million in cash and approximately $73.1 million in outstanding debt.
- Grew the company’s intellectual property portfolio to a current total of 237 global patent applications with 20 issued foreign patents and 19 issued U.S. patents.
“We made important progress during the first half of 2018 that has given us an exciting start to the year,” said Robert G. Finizio, Chief Executive Officer of TherapeuticsMD. “We are focused on commercial and operational execution with the launch of Imvexxy and an approaching PDUFA date for TX-001HR.”
Summary of Second Quarter 2018 Financial Results
Net revenue from the company’s prescription prenatal vitamin business was approximately $3.8 million for the second quarter of 2018 compared with net revenue of approximately $4.3 million for the prior year’s quarter. This decrease was primarily attributable to a decrease in the average net revenue per unit of the company’s products, which was primarily related to higher estimates related to offered discounts in 2018, partially offset by an increase in the number of units sold.
Cost of goods sold was approximately $0.5 million for the second quarter of 2018, compared with approximately $0.7 million for the prior year’s quarter.
Total operating expenses for the second quarter of 2018 included research and development (R&D) expenses and sales, general, and administrative expenses (SG&A). R&D expenses for the second quarter of 2018 were approximately $6.8 million compared with approximately $8.7 million for the prior year’s quarter. The decrease in R&D was a direct result of the completion of the Replenish Trial for TX-001HR. SG&A expenses for the second quarter of 2018 were approximately $29.5 million compared with approximately $14.6 million for the prior year’s quarter, primarily due to higher sales, marketing, and personnel costs to support commercialization of Imvexxy and pre-commercialization expenses for TX-001HR.
Net loss for the second quarter of 2018 was approximately $33.2 million, or $0.15 per basic and diluted share, compared with approximately $19.7 million, or $0.10 per basic and diluted share, for the second quarter of 2017.
Balance Sheet
As of June 30, 2018, the company’s cash on hand totaled approximately $154.4 million, compared with approximately $127.1 million at December 31, 2018. Total outstanding debt, net of issuance of costs, was approximately $73.1 million as of June 30, 2018.
Conference Call and Webcast Details
TherapeuticsMD will host a conference call and audio webcast this morning, July 30, 2018, at 8:30 a.m. ET to present second quarter 2018 results and provide a business update.
|
Date: |
Monday, July 30, 2018 | ||||||
|
Time: |
8:30 a.m. EST | ||||||
|
Telephone Access (US): |
866-665-9531 | ||||||
|
Telephone Access (International): |
724-987-6977 | ||||||
|
Access Code for All Callers: |
8884867 | ||||||
A live webcast and audio archive for the event may be accessed on the home page or from the “Investors & Media” section of the TherapeuticsMD website at www.therapeuticsmd.com. Please connect to the website prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast. A replay of the webcast will be archived on the website for at least 30 days. In addition, a digital recording of the conference call will be available for replay beginning two hours after the call's completion and for at least 30 days with the dial-in 855-859-2056 or international 404-537-3406 and Conference ID: 8884867
About Imvexxy
Imvexxy (estradiol vaginal inserts) is approved in the U.S. for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy (VVA), due to menopause. Imvexxy is the only product in its therapeutic class to offer a 4 mcg and 10 mcg dose, the 4 mcg representing the lowest approved dose of vaginal estradiol available. The full prescribing information may be viewed by visiting www.Imvexxy.com.
IMPORTANT SAFETY INFORMATION FOR IMVEXXY
| WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, BREAST CANCER and PROBABLE DEMENTIA |
|
See full prescribing information for complete boxed warning. |
|
Estrogen-Alone Therapy |
| •There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens |
| •Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or dementia |
| •The Women’s Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT) |
| •The WHI Memory Study (WHIMS) estrogen-alone ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older |
|
Estrogen Plus Progestin Therapy |
| •Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia |
| •The WHI estrogen plus progestin substudy reported increased risks of stroke, DVT, pulmonary embolism (PE) and myocardial infarction (MI) |
| •The WHI estrogen plus progestin substudy reported increased risks of invasive breast cancer |
| •The WHIMS estrogen plus progestin ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older |
CONTRAINDICATIONS
- Imvexxy™ is contraindicated in women with any of the following conditions: undiagnosed abnormal genital bleeding; known, suspected, or history of breast cancer; known or suspected estrogen-dependent neoplasia; active DVT, PE, or history of these conditions; active arterial thromboembolic disease or a history of these conditions; known anaphylactic reaction or angioedema to Imvexxy; known liver impairment or disease; known protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders.
WARNINGS AND PRECAUTIONS
- Imvexxy is intended only for vaginal administration. Systemic absorption may occur with the use of Imvexxy.
- The use of estrogen-alone and estrogen plus progestin therapy has been reported to result in an increase in abnormal mammograms requiring further evaluation.
- The WHI estrogen plus progestin substudy reported a statistically non-significant increased risk of ovarian cancer. A meta-analysis of 17 prospective and 35 retrospective epidemiology studies found that women who used hormonal therapy for menopausal symptoms had an increased risk for ovarian cancer. The exact duration of hormone therapy use associated with an increased risk of ovarian cancer, however, is unknown.
- Other warnings include: gallbladder disease; severe hypercalcemia, loss of vision, severe hypertriglyceridemia or cholestatic jaundice.
- Estrogen therapy may cause an exacerbation of asthma, diabetes mellitus, epilepsy, migraine, porphyria, systemic lupus erythematosus, and hepatic hemangiomas and should be used with caution in women with these conditions.
- Women on thyroid replacement therapy should have their thyroid function monitored.
ADVERSE REACTIONS
- The most common adverse reaction with Imvexxy (incidence ≥ 3 percent) and greater than placebo was headache.
Please note that this information is not comprehensive. Please visit www.Imvexxy.com for the Full Prescribing Information, including the Boxed Warning.
About TherapeuticsMD, Inc.
TherapeuticsMD, Inc. is an innovative healthcare company focused on developing and commercializing products exclusively for women. With its SYMBODA™ technology, TherapeuticsMD is developing advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. The company recently received FDA approval for TX-004HR, branded as Imvexxy™ (estradiol vaginal inserts), for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause. The company’s late stage clinical pipeline includes TX-001HR being evaluated for treatment of moderate-to-severe vasomotor symptoms (VMS) due to menopause. The company also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaMedMD® and BocaGreenMD® brands.
Forward-Looking Statements
This press release by TherapeuticsMD, Inc. may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to TherapeuticsMD’s objectives, plans and strategies as well as statements, other than historical facts, that address activities, events or developments that the company intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,” “plans,” “will,” “expects,” “estimates,” “projects,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and the company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the company’s control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in the company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and include the following: whether the FDA will approve the NDA for the company’s TX-001HR product candidate and whether such approval will occur by the PDUFA target action date; the company’s ability to maintain or increase sales of its products; the company’s ability to develop and commercialize its hormone therapy drug candidates and obtain additional financing necessary therefor; whether the company be able to comply with the covenants and conditions under its term loan agreement; the length, cost and uncertain results of the company’s clinical trials; the potential of adverse side effects or other safety risks that could preclude the approval of the company’s hormone therapy drug candidates or adversely affect the commercialization of the company’s current or future approved products; the company’s reliance on third parties to conduct its clinical trials, research and development and manufacturing; the availability of reimbursement from government authorities and health insurance companies for the company’s products; the impact of product liability lawsuits; the influence of extensive and costly government regulation; the volatility of the trading price of the company’s common stock and the concentration of power in its stock ownership. PDF copies of the company’s historical press releases and financial tables can be viewed and downloaded at its website: www.therapeuticsmd.com/pressreleases.aspx.
|
THERAPEUTICSMD, INC. AND SUBSIDIARIES |
|||||||||
| CONSOLIDATED BALANCE SHEETS | |||||||||
| June 30, 2018 | December 31, 2017 | ||||||||
| (Unaudited) | |||||||||
| ASSETS | |||||||||
| Current Assets: | |||||||||
| Cash | $ | 154,386,930 | $ | 127,135,628 | |||||
|
Accounts receivable, net of allowance for doubtful accounts of $418,604 and $380,580, respectively |
5,625,987 | 4,328,802 | |||||||
| Inventory | 1,880,577 | 1,485,358 | |||||||
| Other current assets | 5,203,734 | 6,604,284 | |||||||
| Total current assets | 167,097,228 | 139,554,072 | |||||||
| Fixed assets, net | 403,574 | 437,055 | |||||||
| Other Assets: | |||||||||
| Intangible assets, net | 3,488,401 | 3,099,747 | |||||||
| Prepaid expenses-long term | 759,229 | - | |||||||
| Security deposit | 150,522 | 139,036 | |||||||
| Total other assets | 4,398,152 | 3,238,783 | |||||||
| Total assets | $ | 171,898,954 | $ | 143,229,910 | |||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||||
| Current Liabilities: | |||||||||
| Accounts payable | $ | 11,427,160 | $ | 4,097,600 | |||||
| Accrued expenses and other current liabilities | 9,785,210 | 9,223,595 | |||||||
| Total current liabilities | 21,212,370 | 13,321,195 | |||||||
| Long-term Liabilities: | |||||||||
| Long-term debt | 73,141,311 | - | |||||||
| Total long-term liabilities | 73,141,311 | - | |||||||
| Total liabilities | 94,353,681 | 13,321,195 | |||||||
| Commitments and Contingencies | |||||||||
| Stockholders' Equity: | |||||||||
|
Preferred stock - par value $0.001; 10,000,000 shares authorized; no shares issued and outstanding |
- | - | |||||||
|
Common stock - par value $0.001; 350,000,000 shares authorized: 216,834,059 and 216,429,642 issued and outstanding, respectively |
216,834 | 216,430 | |||||||
| Additional paid-in capital | 521,608,436 | 516,351,405 | |||||||
| Accumulated deficit | (444,279,997 | ) | (386,659,120 | ) | |||||
| Total stockholders' equity | 77,545,273 | 129,908,715 | |||||||
| Total liabilities and stockholders' equity | $ | 171,898,954 | $ | 143,229,910 | |||||
| THERAPEUTICSMD, INC. AND SUBSIDIARIES | |||||||||||||||||
| CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||||||||||||
| (Unaudited) | |||||||||||||||||
| Three Months Ended | Six Months Ended | ||||||||||||||||
| June 30, | June 30, | ||||||||||||||||
| 2018 | 2017 | 2018 | 2017 | ||||||||||||||
| Revenues, net | $ | 3,763,010 | $ | 4,250,433 | $ | 7,536,402 | $ | 8,235,897 | |||||||||
| Cost of goods sold | 454,161 | 681,725 | 1,087,784 | 1,341,360 | |||||||||||||
| Gross profit | 3,308,849 | 3,568,708 | 6,448,618 | 6,894,537 | |||||||||||||
| Operating expenses: | |||||||||||||||||
| Sales, general, and administration | 29,466,770 | 14,628,927 | 50,224,007 | 31,466,544 | |||||||||||||
| Research and development | 6,798,380 | 8,716,395 | 13,837,677 | 16,441,235 | |||||||||||||
| Depreciation and amortization | 65,603 | 53,189 | 125,224 | 102,888 | |||||||||||||
| Total operating expense | 36,330,753 | 23,398,511 | 64,186,908 | 48,010,667 | |||||||||||||
| Operating loss | (33,021,904 | ) | (19,829,803 | ) | (57,738,290 | ) | (41,116,130 | ) | |||||||||
| Other income (expense): | |||||||||||||||||
| Miscellaneous income | 334,238 | 149,054 | 648,795 | 275,022 | |||||||||||||
| Accreted interest | - | 3,832 | - | 7,699 | |||||||||||||
| Interest expense | (531,382 | ) | - | (531,382 | ) | - | |||||||||||
| Total other (expense) income | (197,144 | ) | 152,886 | 117,413 | 282,721 | ||||||||||||
| Loss before taxes | (33,219,048 | ) | (19,676,917 | ) | (57,620,877 | ) | (40,833,409 | ) | |||||||||
| Provision for income taxes | - | - | - | - | |||||||||||||
| Net loss | $ | (33,219,048 | ) | $ | (19,676,917 | ) | $ | (57,620,877 | ) | $ | (40,833,409 | ) | |||||
| Net loss per share, basic and diluted | $ | (0.15 | ) | $ | (0.10 | ) | $ | (0.27 | ) | $ | (0.20 | ) | |||||
|
Weighted average number of common shares outstanding |
216,640,186 | 203,384,610 | 216,583,067 | 200,602,778 | |||||||||||||
| THERAPEUTICSMD, INC. AND SUBSIDIARIES | |||||||||
| CONSOLIDATED STATEMENTS OF CASH FLOWS | |||||||||
| (Unaudited) | |||||||||
| Six Months Ended | |||||||||
| June 30, 2018 | June 30, 2017 | ||||||||
| CASH FLOWS FROM OPERATING ACTIVITIES | |||||||||
| Net loss | $ | (57,620,877 | ) | $ | (40,833,409 | ) | |||
|
Adjustments to reconcile net loss to net cash flows used in operating activities: |
|||||||||
| Depreciation of fixed assets | 79,201 | 69,000 | |||||||
| Amortization of intangible assets | 46,023 | 33,888 | |||||||
| Provision for (recovery of) doubtful accounts | 38,024 | (18,106 | ) | ||||||
| Share-based compensation | 4,128,440 | 3,051,357 | |||||||
| Amortization of deferred financing costs | 30,155 | - | |||||||
| Changes in operating assets and liabilities: | |||||||||
| Accounts receivable | (1,335,209 | ) | 1,122,386 | ||||||
| Inventory | (395,219 | ) | (337,694 | ) | |||||
| Other current assets | 2,539,394 | (58,601 | ) | ||||||
| Accounts payable | 7,329,560 | 749,520 | |||||||
| Accrued interest | 501,227 | - | |||||||
| Accrued expenses and other current liabilities | 60,388 | (2,443,867 | ) | ||||||
| Net cash used in operating activities | (44,598,893 | ) | (38,665,526 | ) | |||||
| CASH FLOWS FROM INVESTING ACTIVITIES | |||||||||
| Patent costs | (434,677 | ) | (367,602 | ) | |||||
| Purchase of fixed assets | (45,720 | ) | (35,849 | ) | |||||
| Payment of security deposit | (11,486 | ) | - | ||||||
| Net cash used in investing activities | (491,883 | ) | (403,451 | ) | |||||
| CASH FLOWS FROM FINANCING ACTIVITIES | |||||||||
| Proceeds from term loan | 75,000,000 | - | |||||||
| Payment of deferred financing fees | (3,786,918 | ) | - | ||||||
| Proceeds from exercise of options | 1,128,996 | 212,360 | |||||||
| Proceeds from exercise of warrants | - | 3,798,999 | |||||||
| Net cash provided by financing activities | 72,342,078 | 4,011,359 | |||||||
| Increase (decrease) in cash | 27,251,302 | (35,057,618 | ) | ||||||
| Cash, beginning of period | 127,135,628 | 131,534,101 | |||||||
| Cash, end of period | $ | 154,386,930 | $ | 96,476,483 | |||||
